Po-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, Wei Teng, Yi-Chung Hsieh, Wei-Ting Chen, Chung-Wei Su, Ching-Ting Wang, Pei-Mei Chai, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin
For advanced hepatocellular carcinoma (HCC), the best second-line treatment after first-line treatment with sorafenib is unclear. This study aimed to compared the efficacy of second-line regorafenib (a tyrosine kinase inhibitor) and immune checkpoint inhibitors (ICIs) in patients with advanced HCC after sorafenib therapy. This retrospective study included 89 patients with HCC treated with sorafenib, and then regorafenib (n = 58) or an ICI (n = 31). Treatment response, overall survival (OS) and progression-free survival (PFS) of the 2 groups were compared, and factors associated with post-treatment mortality or disease progression were evaluated...
2024: American Journal of Cancer Research